The Peter Doherty Institute of Infectious and Immunology will join Monash University, the University of Melbourne and a number of other research centers as the recipients of funding to develop the above plan. Vaccination against Covid-19 in Australia is facing many challenges due to lack of supply. (Source: Reuters) Scientists at the Peter Doherty Institute said they are working on a “preventive” vaccine with mRNA technology that can be modified to fight variations. Mr. Merlino said that this plan is an important event, not only for Victoria but for the entire country of Australia. Besides, he affirmed that the support budget will be increased when the project is developed in the future. Australia is currently only capable of producing AstraZeneca’s vaccines, with the initial plan being that the CSL facility in the city of Melbourne will produce more than 50 million doses. Vaccination against Covid-19 in Australia is facing many challenges due to the lack of vaccine supply, as well as the safety of the vaccine in relation to the side effects of thrombosis. (Reuters)

Acting Premier of Victoria, James Merlino. (Source: abc.net.au) On the morning of April 21, Mr. James Merlino, acting Premier of Victoria ( Australia ) announced that it would provide AUD 50 million (approximately US $ 38.6 million) to launch a project to develop vaccine production technology for mRNA at state vaccine research facilities. Under the project, it will take at least 12 months for Australia to be able to produce any vaccine under it mRNA technology . The move will pave the way for vaccines using mRNA technology such as Pfizer and Moderna to be produced in Australia, according to the Vietnam News Agency correspondent in Sydney. The Peter Doherty Institute of Infectious and Immunology will join Monash University, the University of Melbourne and a number of other research centers as the recipients of the funding to develop the above plan. Scientists at the Peter Doherty Institute say they are working on a “preventive” vaccine with mRNA technology that can be modified to fight variations. Mr. Merlino said that this plan is an important event, not only for Victoria but for the whole of Australia. Besides, he affirmed that the support budget will be increased when the project is developed in the future. Australia is currently only capable vaccine production of AstraZeneca with the initial plan that the CSL facility in the city of Melbourne will produce more than 50 million doses. Vaccination work COVID-19 Australia is facing many challenges due to the lack of vaccine supplies, as well as the safety of this vaccine related to the side effects of thrombosis.